This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
HQY Stock Falls as Q4 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
HealthEquity surpasses fourth-quarter revenue expectations on robust HSA growth. It also provided fiscal 2026 guidance.
Here's Why you Should Retain Nevro Stock in Your Portfolio Now
by Zacks Equity Research
NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.
Here's Why You Should Retain AMED Stock in Your Portfolio Now
by Zacks Equity Research
Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
Should You Hold Globus Medical Stock in Your Portfolio Now?
by Zacks Equity Research
GMED stays on investors' radar due to its high NuVasive-merger synergies and solid Musculoskeletal prospects.
TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology
by Zacks Equity Research
Tandem Diabetes launches Control-IQ+ technology commercially in the United States. Control-IQ+ is compatible with t:slim X2 insulin pump and Tandem Mobi System.
Boston Scientific (BSX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
The latest trading day saw Boston Scientific (BSX) settling at $99.22, representing a +0.32% change from its previous close.
HYPR Stock Jumps on NVIDIA Partnership to Advance AI Neuroimaging
by Zacks Equity Research
Hyperfine partners with NVIDIA to integrate advanced AI into its Swoop MRI system, aiming to transform neuroimaging with faster and more accessible brain scan solutions.
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
by Zacks Equity Research
Strong prospects for the Hospital Business and the robust NexSys PCS system bode well for Haemonetics.
Should You Retain IDEXX Stock in Your Portfolio for Now?
by Zacks Equity Research
IDXX stays on investors' radar due to the strength of its CAG Diagnostics business.
Here's Why You Should Retain Surmodics Stock in Your Portfolio Now
by Zacks Equity Research
SRDX stock falls more than 26% so far this year. However, this provides a unique opportunity to generate double-digit returns within a couple of months.
Boston Scientific (BSX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Boston Scientific (BSX) closed at $98.90 in the latest trading session, marking a +1.79% move from the prior day.
Will ISRG Stock Drop Continue After da Vinci 5 Recall?
by Zacks Equity Research
Intuitive Surgical faces a Class 2 recall for its da Vinci 5 system due to a pedal issue. Will this affect its 2025 rollout? Investors watch closely!
Lifeward Stock Falls Despite FDA Clearance of ReWalk 7 Exoskeleton
by Zacks Equity Research
LFWD secures FDA clearance for its ReWalk 7 Exoskeleton, introducing enhanced features to empower individuals with spinal cord injury and expand mobility options.
Compelling Weight Management Program Data Set to Boost CVS Stock
by Zacks Equity Research
CVS Health shares impressive findings from its Weight Management Program.
PAHC vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. BSX: Which Stock Is the Better Value Option?
MMSI Announces Commencement of Patient Enrollment in PREEMIE Study
by Zacks Equity Research
Merit Medical aims to improve care for vulnerable premature infants by evaluating the safety and efficacy of the Bloom Micro Occluder System for treating PDA in the specified patient pool.
Tempus Stock May Rise on the Acquisition of AI-Driven Deep 6 AI
by Zacks Equity Research
TEM announces the acquisition of Deep 6 AI, enhancing its AI-driven clinical trial matching capabilities to accelerate patient recruitment and revolutionize precision medicine.
Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?
by Zacks Equity Research
Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and WATCHMAN's performance.
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally?
by Zacks Equity Research
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Is it the Right Time to Hold Alcon Stock in Your Portfolio Now?
by Zacks Equity Research
ALC stays on investors' radar due to its Surgical arm performance and contributions from new products.
Here's Why You Should Retain Glaukos Stock in Your Portfolio
by Zacks Equity Research
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Stryker Unveils Next-Generation Mako SmartRobotics but Stock Falls
by Zacks Equity Research
SYK unveils next-gen Mako SmartRobotics, revolutionizing hip, knee and spine surgeries with greater precision and first-to-market robotic hip revision technology.
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Continue to Retain STERIS Stock in Your Portfolio Now?
by Zacks Equity Research
Investors continue to keep an eye on STE due to its promising Healthcare arm and AST segment's prospects.
Here's Why You Should Add Veeva Systems Stock to Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.